EZH2 and Familial prostate cancer: We hypothesize that the AR/DPYSL5/EZH2/PRC2 axis is a novel mechanism underlying prostate cancer progression to t-NEPC, and it is important to further elucidate the theranostic potential of DPYSL5 and explore any pharmacological strategies that could manipulate its expression.